Benefits of CBD

Evidence-Based Benefits

• Anxiety reduction — Shannon et al. (2019) documented reduced anxiety scores in 79.2% of 72 patients at a psychiatric clinic taking 25-175mg CBD daily, with improvement maintained over the 3-month observation period
• Public speaking anxiety — Linares et al. (2019) conducted a double-blind RCT showing 300mg CBD significantly reduced anxiety during a simulated public speaking test compared to placebo, with an inverted U-shaped dose response (150mg and 600mg were less effective than 300mg)
• Sleep improvement — in the Shannon case series, 66.7% of patients reported improved sleep scores in the first month, though scores fluctuated over time, suggesting CBD's sleep effects may be partly mediated through anxiety reduction
• Serotonin 5-HT1A agonism — Russo et al. (2005) and subsequent research showed CBD acts as an agonist at serotonin 5-HT1A receptors, which are a key target for anxiolytic and antidepressant medications
• Anti-inflammatory neuroprotection — CBD reduces neuroinflammation via CB2 receptor and non-cannabinoid pathways, potentially addressing inflammation-driven sleep and mood disturbances

What the Research Says

CBD has rapidly growing but still emerging evidence for anxiety and sleep. Shannon et al. (2019) provided the largest clinical observation, but it was a retrospective case series, not an RCT. Linares et al. (2019) provided the strongest RCT evidence for acute anxiety, showing an inverted U-shaped dose response peaking at 300mg. Zuardi et al. (1993) was an early RCT demonstrating CBD's anxiolytic effects in a simulated public speaking test. The sleep evidence is weaker — most studies note sleep improvement as a secondary outcome of anxiety reduction. The main concerns are regulatory inconsistency (CBD product quality varies enormously), significant CYP450 drug interactions, and the limited number of large, well-designed RCTs. The FDA has only approved CBD (as Epidiolex) for specific epilepsy conditions, not for anxiety or sleep.

Related Conditions